We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Paper Diagnostic Directly Measures Fibrinogen in Whole Blood

By LabMedica International staff writers
Posted on 10 Nov 2020
Fibrinogen is a protein found in blood that is needed for clotting. More...
When a patient experiences traumatic injury, such as a serious car accident, or major surgery and childbirth complications, fibrinogen is required in their blood to prevent major hemorrhaging and death from blood loss.

Typically, heavily bleeding patients must be transported to a hospital or emergency center where they undergo diagnostic tests before being treated. These tests are time consuming and costly as they require expensive equipment, specialized or trained personnel and can take up to half an hour. More than 20% of major trauma patients have hyperfibrinogenemia.

Chemical Engineers at Monash University (Clayton, Australia) developed a handheld fibrinogen diagnostic device that works with whole blood. The test works by placing a pre-mixed droplet of a blood sample and an enzyme solution onto a solid surface, allowing it to clot, and then dropping a paper strip on top. The further that blood moves down the strip of paper, the lower the fibrinogen concentration. The diagnostic can work with a variety of blood conditions. Furthermore, diluting blood samples not only increases the test's sensitivity, but also eliminates the effect of interfering substances in the blood.

The further that blood moves down the strip, the lower the fibrinogen concentration. The diagnostic can easily measure plasma fibrinogen concentrations below 1.6 g/L for blood samples with hematocrits between 40 and 50%. The test can be completed in 3 to 4 minutes, making it suitable for diagnosing early hypofibrinogenemia and allowing for fibrinogen replacement therapy in critically bleeding patients.

Gil Garnier, PhD, a Professor of Chemical Engineering and senior author of the study, said, “This diagnostic will allow emergency doctors and paramedics to quickly and accurately diagnose low levels of fibrinogen in patients, giving them faster access to life-saving treatment to stop critical bleeding. When a patient is bleeding heavily and has received several blood transfusions, their levels of fibrinogen drop. Even after dozens of transfusions, patients keep bleeding. What they need is an injection of fibrinogen. However, if patients receive too much fibrinogen, they can also die.” The study was published on October 23, 2020 in the journal ACS Sensors.

Related Links:
Monash University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.